Anti-PD-1 antibody therapy for epithelial skin malignancies
M Ishii(Keio University), Takeru Funakoshi(Keio University), Takayuki Fusumae(Keio University), Yasunori Sato(Keio University), Keiji Tanese(Toho University), Kenji Kabashima(Kyoto University), Mana Nishiguchi(Wakayama Medical University), Taku Fujimura(Université Paris Cité), Naoya Yamazaki(Tokyo National Hospital), Yoshio Nakamura(Keio University), Ikuko Hirai(Keio University), Atsushi Otsuka(Kyoto University), Keitaro Fukuda, Tatsuya Takenouchi(Niigata Cancer Center Hospital), Yuki Yamamoto(National Center For Child Health and Development), Masayuki Amagai(Keio University), Kenji Yokota(International Research Center for Japanese Studies), Kenjiro Namikawa(Tokyo Metropolitan Komagome Hospital), Hiroshi Uchi(Kyushu University)
Cited by 24
Related Papers
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
|Frontiers in Oncology|2018|1.3k
Inflammation-free, gas-permeable, lightweight, stretchable on-skin electronics with nanomeshes
|Nature Nanotechnology|2017|1.1k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k